FATE
Price
$1.27
Change
+$0.02 (+1.60%)
Updated
Jan 17 closing price
Capitalization
144.65M
44 days until earnings call
SLRN
Price
$1.99
Change
-$0.00 (-0.00%)
Updated
Jan 17 closing price
Capitalization
199.65M
68 days until earnings call
Ad is loading...

FATE vs SLRN

Header iconFATE vs SLRN Comparison
Open Charts FATE vs SLRNBanner chart's image
Fate Therapeutics
Price$1.27
Change+$0.02 (+1.60%)
Volume$1.27M
Capitalization144.65M
ACELYRIN
Price$1.99
Change-$0.00 (-0.00%)
Volume$766.57K
Capitalization199.65M
FATE vs SLRN Comparison Chart
Loading...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLRN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
FATE vs. SLRN commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FATE is a Hold and SLRN is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (FATE: $1.27 vs. SLRN: $1.99)
Brand notoriety: FATE and SLRN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FATE: 32% vs. SLRN: 68%
Market capitalization -- FATE: $144.65M vs. SLRN: $199.65M
FATE [@Biotechnology] is valued at $144.65M. SLRN’s [@Biotechnology] market capitalization is $199.65M. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FATE’s FA Score shows that 1 FA rating(s) are green whileSLRN’s FA Score has 1 green FA rating(s).

  • FATE’s FA Score: 1 green, 4 red.
  • SLRN’s FA Score: 1 green, 4 red.
According to our system of comparison, both FATE and SLRN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FATE’s TA Score shows that 3 TA indicator(s) are bullish while SLRN’s TA Score has 4 bullish TA indicator(s).

  • FATE’s TA Score: 3 bullish, 3 bearish.
  • SLRN’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both FATE and SLRN are a good buy in the short-term.

Price Growth

FATE (@Biotechnology) experienced а -13.31% price change this week, while SLRN (@Biotechnology) price change was -3.40% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

FATE is expected to report earnings on Apr 30, 2025.

SLRN is expected to report earnings on Mar 27, 2025.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SLRN($200M) has a higher market cap than FATE($145M). FATE YTD gains are higher at: -23.030 vs. SLRN (-36.624). FATE has higher annual earnings (EBITDA): -177.57M vs. SLRN (-324.52M). SLRN has more cash in the bank: 562M vs. FATE (297M). SLRN has less debt than FATE: SLRN (6.56M) vs FATE (99M). FATE has higher revenues than SLRN: FATE (13.4M) vs SLRN (0).
FATESLRNFATE / SLRN
Capitalization145M200M73%
EBITDA-177.57M-324.52M55%
Gain YTD-23.030-36.62463%
P/E RatioN/AN/A-
Revenue13.4M0-
Total Cash297M562M53%
Total Debt99M6.56M1,510%
FUNDAMENTALS RATINGS
FATE: Fundamental Ratings
FATE
OUTLOOK RATING
1..100
66
VALUATION
overvalued / fair valued / undervalued
1..100
14
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
97
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
FATESLRN
RSI
ODDS (%)
N/A
Bullish Trend 11 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 11 days ago
89%
Bullish Trend 11 days ago
90%
Momentum
ODDS (%)
Bullish Trend 11 days ago
82%
Bearish Trend 11 days ago
90%
MACD
ODDS (%)
Bullish Trend 11 days ago
85%
Bearish Trend 11 days ago
71%
TrendWeek
ODDS (%)
Bullish Trend 11 days ago
84%
Bearish Trend 11 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 11 days ago
90%
Bearish Trend 11 days ago
90%
Advances
ODDS (%)
Bullish Trend 13 days ago
86%
Bullish Trend 16 days ago
78%
Declines
ODDS (%)
Bearish Trend 11 days ago
90%
Bearish Trend 11 days ago
90%
BollingerBands
ODDS (%)
N/A
Bullish Trend 11 days ago
80%
Aroon
ODDS (%)
Bearish Trend 11 days ago
90%
Bearish Trend 11 days ago
90%
View a ticker or compare two or three
Ad is loading...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLRN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SMAPX11.280.07
+0.62%
Westwood Salient MLP & Engy Infras A
MADRX26.020.14
+0.54%
Madison Dividend Income R6
MSHPX13.440.07
+0.52%
Morgan Stanley Inst Permanence R6
POSKX34.780.15
+0.43%
PRIMECAP Odyssey Stock
GCAEX6.10N/A
N/A
Gabelli Equity Income A

SLRN and

Correlation & Price change

A.I.dvisor indicates that over the last year, SLRN has been loosely correlated with CMND. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if SLRN jumps, then CMND could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLRN
1D Price
Change %
SLRN100%
N/A
CMND - SLRN
38%
Loosely correlated
-1.97%
TRML - SLRN
37%
Loosely correlated
+3.87%
THAR - SLRN
36%
Loosely correlated
+1.50%
OLMA - SLRN
36%
Loosely correlated
+7.20%
FATE - SLRN
35%
Loosely correlated
+1.60%
More